TrialDiabetes, obesity & metabolism2014

Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.

S S Torekov et al.PubMed ↗Publisher ↗

No numbers read from the abstract.